Mankind Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	153,786	142,776	122,074	102,604	87,494	77,816
Revenue Growth	13.53%	16.96%	18.98%	17.27%	12.44%	25.22%
Cost of Revenue	44,513	42,646	36,676	33,056	30,031	24,879
Gross Profit	109,273	100,130	85,399	69,549	57,463	52,937
Selling, General & Admin	42,663	40,124	34,734	28,830	23,126	20,934
Other Operating Expenses	24,964	22,954	19,370	15,432	15,195	12,014
Operating Expenses	76,697	71,939	60,316	48,047	41,580	34,614
Operating Income	32,575	28,191	25,083	21,502	15,883	18,322
Interest Expense	-5,080	-6,334	-4,209	-278.2	-402.74	-557.8
Interest & Investment Income	580.5	580.5	679.1	396.1	127.67	129.25
Earnings From Equity Investments	138.2	116.9	122.4	152.1	124.24	144.48
Currency Exchange Gain (Loss)	700.1	700.1	195.5	84.4	104.06	88.45
Other Non Operating Income (Expenses)	-184.5	134.5	102.8	878.6	536.42	486
EBT Excluding Unusual Items	28,730	23,389	21,974	22,735	16,372	18,613
Impairment of Goodwill	-	-	-	-	-38.52	-
Gain (Loss) on Sale of Investments	1,272	1,272	1,608	1,295	374.31	1,129
Gain (Loss) on Sale of Assets	-23.1	-23.1	1,614	4.8	16.65	-37.41
Asset Writedown	-256.8	-256.8	-50.2	-91.6	-97.08	-57.63
Other Unusual Items	-1,088	-1,088	8.1	24.8	41.53	85.27
Pretax Income	28,667	23,327	25,163	23,979	16,712	19,746
Income Tax Expense	6,032	3,946	5,097	4,572	3,616	5,216
Earnings From Continuing Operations	22,635	19,381	20,066	19,408	13,097	14,530
Earnings From Discontinued Operations	-	-	45.3	9.8	-	-
Net Income to Company	22,635	19,381	20,111	19,418	13,097	14,530
Minority Interest in Earnings	-208.7	-251.7	-201.6	-288.7	-278.17	-194.81
Net Income	22,426	19,129	19,910	19,129	12,819	14,335
Net Income to Common	22,426	19,129	19,910	19,129	12,819	14,335
Net Income Growth	28.09%	-3.92%	4.08%	49.23%	-10.58%	13.28%
Shares Outstanding (Basic)	413	413	404	401	401	401
Shares Outstanding (Diluted)	413	413	405	401	401	401
Shares Change	0.67%	2.13%	0.88%	0.14%	0.00%	-
EPS (Basic)	54.33	46.35	49.28	47.75	32.00	35.78
EPS (Diluted)	54.24	46.28	49.19	47.68	32.00	35.78
EPS Growth	27.25%	-5.92%	3.16%	49.02%	-10.57%	13.27%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	25,390	24,953	19,526	18,371	10,243	4,549
Free Cash Flow Per Share	61.41	60.37	48.25	45.79	25.57	11.36
Gross Margin	71.06%	70.13%	69.96%	67.78%	65.68%	68.03%
Operating Margin	21.18%	19.74%	20.55%	20.96%	18.15%	23.55%
Profit Margin	14.58%	13.40%	16.31%	18.64%	14.65%	18.42%
Free Cash Flow Margin	16.51%	17.48%	16.00%	17.90%	11.71%	5.85%
EBITDA	40,894	36,301	30,909	25,152	19,051	19,910
EBITDA Margin	26.59%	25.42%	25.32%	24.51%	21.77%	25.59%
D&A For EBITDA	8,319	8,110	5,827	3,649	3,168	1,588
EBIT	32,575	28,191	25,083	21,502	15,883	18,322
EBIT Margin	21.18%	19.74%	20.55%	20.96%	18.15%	23.55%
Effective Tax Rate	21.04%	16.91%	20.26%	19.06%	21.63%	26.42%
Revenue as Reported	157,055	146,364	127,442	105,407	88,780	79,776
Advertising Expenses	-	7,978	7,554	6,008	3,737	4,516